OverviewSuggest Edit
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
| Type | Public | |
| Founded | 1998 | |
| HQ | Bethesda, US | Map |
| Website | nwbio.com | |
| Employee Ratings | More |
Latest Updates
| Employees (est.) (Feb 2019) | 14 | (+40%) |
| Revenue (FY, 2017) | $336 K | (-46%) |
Key People/Management at Northwest Biotherapeutics
Linda F. Powers
Marnix L. Bosch
Anthony Maida
Alton L. Boynton
Northwest Biotherapeutics Office Locations
Northwest Biotherapeutics Financials and Metrics
Northwest Biotherapeutics Revenue
| USD | |
|---|---|
Revenue (Q3, 2018) | 453.0k |
Net income (Q3, 2018) | 12.6m |
EBIT (Q3, 2018) | (9.3m) |
Market capitalization (9-Oct-2018) | 234.2m |
Cash (30-Sep-2018) | 248.0k |
EV | 238.0m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 400.0k | 582.0k | 391.0k | 291.0k | 236.0k | 157.0k | 159.0k | 68.0k | 88.0k | 148.0k | 132.0k | 278.0k | 453.0k | ||
General and administrative expense | 9.8m | 4.3m | 4.3m | 6.5m | 4.6m | 3.0m | 3.3m | 3.0m | 3.0m | 14.4m | 3.5m | ||||
R&D expense | 12.8m | 20.0m | 21.5m | 22.7m | 29.4m | 9.2m | 13.4m | 8.7m | 5.0m | 5.5m | 9.7m | 4.7m | 5.3m | 4.3m | |
Operating expense total | 15.9m | 23.7m | 25.4m | 27.2m | 39.2m | 13.5m | 17.7m | 15.2m | 25.7m | 12.0m | 10.8m | 14.3m | 8.9m | 20.6m | 9.8m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.9m | 12.2m | 8.9m | 1.4m | 19.2m | 5.4m | 11.7m | 2.1m | 802.0k | 1.8m | 22.0k | 1.1m | 198.0k | 1.6m | 248.0k |
Current Assets | 7.5m | 12.4m | 12.4m | 1.6m | 21.2m | 7.1m | 13.5m | 4.5m | 2.3m | 3.2m | 819.0k | 2.1m | 1.1m | 2.4m | 1.1m |
PP&E | 140.0k | 80.0k | 77.0k | 23.9m | 42.0m | 44.0m | 48.4m | 46.9m | 46.6m | 261.0k | 224.0k | 188.0k | 48.6m | 46.0m | 45.1m |
Total Assets | 7.6m | 12.5m | 12.6m | 29.4m | 64.2m | 51.6m | 62.2m | 51.6m | 48.9m | 48.3m | 47.4m | 49.7m | 49.8m | 48.5m | 46.3m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (48.9m) | (46.0m) | (71.9m) | (92.9m) | (113.3m) | (90.7m) | (6.1m) | (20.3m) | (49.5m) | (12.6m) | (22.9m) | (46.1m) | (21.5m) | (42.7m) | (30.1m) |
Depreciation and Amortization | 9.0k | 3.0k | 6.0k | 352.0k | 15.0k | 44.0k | 13.0k | 80.0k | 135.0k | 56.0k | 100.0k | 141.0k | 365.0k | 722.0k | 1.1m |
Accounts Payable | 1.1m | 277.0k | 1.4m | 3.7m | 2.2m | 7.1m | (3.1m) | 628.0k | 1.7m | 514.0k | 3.2m | 4.4m | (628.0k) | 857.0k | 4.5m |
Cash From Operating Activities | (23.2m) | (10.6m) | (27.5m) | (36.0m) | (44.7m) | (56.5m) | (17.6m) | (31.8m) | (41.6m) | (12.3m) | (16.0m) | (21.7m) | (4.8m) | (16.4m) | (20.4m) |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -25.5 x |
EV/CFO | -11.7 x |
Financial Leverage | -1 x |
Northwest Biotherapeutics Online and Social Media Presence
2.01k Twitter followers
Northwest Biotherapeutics has 2.01k Twitter Followers. The number of followers has increased 0.2% month over month and decreased 1.6% quarter over quarter
Northwest Biotherapeutics News and Updates
Product Overview and Scope of Worldwide Castration Resistant Prostate Cancer Treatment Market forecast 2025 | TOP Key Players - Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceu
Northwest Biotherapeutics Blogs
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma
NW Bio Announces $5 Million Bridge Funding
Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit
NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit
Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018
Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018
Northwest Biotherapeutics Frequently Asked Questions
When was Northwest Biotherapeutics founded?
Northwest Biotherapeutics was founded in 1998.
Who are Northwest Biotherapeutics key executives?
Northwest Biotherapeutics's key executives are Linda F. Powers, Marnix L. Bosch and Anthony Maida.
How many employees does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 14 employees.
What is Northwest Biotherapeutics revenue?
Latest Northwest Biotherapeutics annual revenue is $336 k.
What is Northwest Biotherapeutics revenue per employee?
Latest Northwest Biotherapeutics revenue per employee is $24 k.
Who are Northwest Biotherapeutics competitors?
Competitors of Northwest Biotherapeutics include Merrimack Pharmaceuticals, TESARO and AVEO Pharmaceuticals.
Where is Northwest Biotherapeutics headquarters?
Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.
Where are Northwest Biotherapeutics offices?
Northwest Biotherapeutics has an office in Bethesda.
How many offices does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 1 office.